213 related articles for article (PubMed ID: 18411709)
21. Intracisternal A-particle element in the 3' noncoding region of the mu-opioid receptor gene in CXBK mice: a new genetic mechanism underlying differences in opioid sensitivity.
Han W; Kasai S; Hata H; Takahashi T; Takamatsu Y; Yamamoto H; Uhl GR; Sora I; Ikeda K
Pharmacogenet Genomics; 2006 Jun; 16(6):451-60. PubMed ID: 16708053
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenetics in pain management: the clinical need.
Webster LR
Clin Lab Med; 2008 Dec; 28(4):569-79. PubMed ID: 19059063
[TBL] [Abstract][Full Text] [Related]
23. Acute and chronic fentanyl administration causes hyperalgesia independently of opioid receptor activity in mice.
Waxman AR; Arout C; Caldwell M; Dahan A; Kest B
Neurosci Lett; 2009 Oct; 462(1):68-72. PubMed ID: 19559072
[TBL] [Abstract][Full Text] [Related]
24. Effect of genetic factors on opioid action.
Kosarac B; Fox AA; Collard CD
Curr Opin Anaesthesiol; 2009 Aug; 22(4):476-82. PubMed ID: 19502975
[TBL] [Abstract][Full Text] [Related]
25. Receptor trafficking induced by mu-opioid-receptor phosphorylation.
Zhang Y; Xiong W; Lin X; Ma X; Yu LC
Neurosci Biobehav Rev; 2009 Sep; 33(8):1192-7. PubMed ID: 19747597
[TBL] [Abstract][Full Text] [Related]
26. The Rac GTPase-activating bacterial protein toxin CNF1 induces analgesia up-regulating mu-opioid receptors.
Pavone F; Luvisetto S; Marinelli S; Straface E; Fabbri A; Falzano L; Fiorentini C; Malorni W
Pain; 2009 Sep; 145(1-2):219-29. PubMed ID: 19608345
[TBL] [Abstract][Full Text] [Related]
27. Association of morphine-induced antinociception with variations in the 5' flanking and 3' untranslated regions of the mu opioid receptor gene in 10 inbred mouse strains.
Shigeta Y; Kasai S; Han W; Hata H; Nishi A; Takamatsu Y; Hagino Y; Yamamoto H; Koide T; Shiroishi T; Kasai K; Tsunashima K; Kato N; Ikeda K
Pharmacogenet Genomics; 2008 Nov; 18(11):927-36. PubMed ID: 18854775
[TBL] [Abstract][Full Text] [Related]
28. Is there genetic polymorphism evidence for individual human sensitivity to opiates?
Nagashima M; Katoh R; Sato Y; Tagami M; Kasai S; Ikeda K
Curr Pain Headache Rep; 2007 Apr; 11(2):115-23. PubMed ID: 17367590
[TBL] [Abstract][Full Text] [Related]
29. Morphine inhibits herpetic allodynia through mu-opioid receptors induced in Abeta-fiber neurons.
Sasaki A; Nakashima Y; Takasaki I; Andoh T; Shiraki K; Kuraishi Y
Neuroreport; 2008 Jun; 19(9):975-9. PubMed ID: 18521004
[TBL] [Abstract][Full Text] [Related]
30. Variable response to opioid treatment: any genetic predictors within sight?
Skorpen F; Laugsand EA; Klepstad P; Kaasa S
Palliat Med; 2008 Jun; 22(4):310-27. PubMed ID: 18541635
[TBL] [Abstract][Full Text] [Related]
31. Mu-opioid receptor activation induces transcriptional plasticity in the central extended amygdala.
Befort K; Filliol D; Ghate A; Darcq E; Matifas A; Muller J; Lardenois A; Thibault C; Dembele D; Le Merrer J; Becker JA; Poch O; Kieffer BL
Eur J Neurosci; 2008 Jun; 27(11):2973-84. PubMed ID: 18588537
[TBL] [Abstract][Full Text] [Related]
32. Opiate receptors: a review of analgesic properties and pharmacological side effects.
Poole JC; Jahr JS
J La State Med Soc; 1992 Mar; 144(3):106-8. PubMed ID: 1324287
[TBL] [Abstract][Full Text] [Related]
33. Outcomes after intravenous opioids in emergency patients: a prospective cohort analysis.
O'Connor AB; Zwemer FL; Hays DP; Feng C
Acad Emerg Med; 2009 Jun; 16(6):477-87. PubMed ID: 19426295
[TBL] [Abstract][Full Text] [Related]
34. Deletion of mu-opioid receptor in mice alters the development of acute neuroinflammation.
Benamar K; Yondorf M; Barreto VT; Geller EB; Adler MW
J Pharmacol Exp Ther; 2007 Dec; 323(3):990-4. PubMed ID: 17898318
[TBL] [Abstract][Full Text] [Related]
35. Current evidence for a genetic modulation of the response to analgesics.
Lötsch J; Geisslinger G
Pain; 2006 Mar; 121(1-2):1-5. PubMed ID: 16472919
[No Abstract] [Full Text] [Related]
36. Opioids and cancer survivors: issues in side-effect management.
Palos GR
Oncol Nurs Forum; 2008 Nov; 35 Suppl():13-9. PubMed ID: 18980935
[TBL] [Abstract][Full Text] [Related]
37. Buprenorphine signalling is compromised at the N40D polymorphism of the human μ opioid receptor in vitro.
Knapman A; Santiago M; Connor M
Br J Pharmacol; 2014 Sep; 171(18):4273-88. PubMed ID: 24846673
[TBL] [Abstract][Full Text] [Related]
38. [Genetic polymorphisms commonly associated with sensitivity to various addictive substances].
Nishizawa D; Ikeda K
Nihon Shinkei Seishin Yakurigaku Zasshi; 2013 Nov; 33(5-6):205-9. PubMed ID: 25069259
[TBL] [Abstract][Full Text] [Related]
39. Current developments in opioid therapy for management of cancer pain.
de Leon-Casasola OA
Clin J Pain; 2008 May; 24 Suppl 10():S3-7. PubMed ID: 18418225
[TBL] [Abstract][Full Text] [Related]
40. [Are polymorphisms in the mu-opioid receptor important for opioid therapy?].
Lötsch J; Freynhagen R; Geisslinger G
Schmerz; 2005 Oct; 19(5):378-82, 384-5. PubMed ID: 16133302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
